company background image
NAN

NanosonicsASX:NAN Stock Report

Market Cap

AU$2.0b

7D

3.5%

1Y

12.3%

Updated

26 Sep, 2021

Data

Company Financials +
NAN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance1/6
Financial Health6/6
Dividends0/6

NAN Overview

Nanosonics Limited, together with its subsidiaries, operates as an infection prevention company in Australia and internationally.

Rewards

Earnings are forecast to grow 27.44% per year

Risk Analysis

No risks detected for NAN from our risk checks.

Nanosonics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nanosonics
Historical stock prices
Current Share PriceAU$6.49
52 Week HighAU$4.89
52 Week LowAU$8.25
Beta1.24
1 Month Change-3.99%
3 Month Change11.13%
1 Year Change12.28%
3 Year Change80.78%
5 Year Change91.45%
Change since IPO691.46%

Recent News & Updates

Aug 03
Returns Are Gaining Momentum At Nanosonics (ASX:NAN)

Returns Are Gaining Momentum At Nanosonics (ASX:NAN)

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...

Shareholder Returns

NANAU Medical EquipmentAU Market
7D3.5%-3.7%-0.9%
1Y12.3%5.3%24.4%

Return vs Industry: NAN exceeded the Australian Medical Equipment industry which returned 5.3% over the past year.

Return vs Market: NAN underperformed the Australian Market which returned 24.4% over the past year.

Price Volatility

Is NAN's price volatile compared to industry and market?
NAN volatility
NAN Beta1.24
Industry Beta0.54
Market Beta1

Stable Share Price: NAN is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: NAN's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2000339Michael Kavanaghhttps://www.nanosonics.com.au

Nanosonics Limited, together with its subsidiaries, operates as an infection prevention company in Australia and internationally. The company engages in the manufacturing and distribution of the trophon ultrasound probe disinfector, and its associated consumables and accessories; and research, development, and commercialization of infection control and decontamination products and related technologies. It provides trophon2, an ultrasound probe high level disinfection device; trophon EPR, a low temperature high level disinfection solution for intra-cavity ultrasound probes; and Nanosonics AuditPro, an infection control workflow compliance management solution.

Nanosonics Fundamentals Summary

How do Nanosonics's earnings and revenue compare to its market cap?
NAN fundamental statistics
Market CapAU$1.96b
Earnings (TTM)AU$8.58m
Revenue (TTM)AU$103.08m

228.3x

P/E Ratio

19.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NAN income statement (TTM)
RevenueAU$103.08m
Cost of RevenueAU$22.70m
Gross ProfitAU$80.38m
ExpensesAU$71.81m
EarningsAU$8.58m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.028
Gross Margin77.98%
Net Profit Margin8.32%
Debt/Equity Ratio0%

How did NAN perform over the long term?

See historical performance and comparison

Valuation

Is Nanosonics undervalued compared to its fair value and its price relative to the market?

228.28x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: NAN (A$6.49) is trading above our estimate of fair value (A$3.67)

Significantly Below Fair Value: NAN is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: NAN is poor value based on its PE Ratio (228.3x) compared to the Australian Medical Equipment industry average (13.3x).

PE vs Market: NAN is poor value based on its PE Ratio (228.3x) compared to the Australian market (19.1x).


Price to Earnings Growth Ratio

PEG Ratio: NAN is poor value based on its PEG Ratio (8.3x)


Price to Book Ratio

PB vs Industry: NAN is overvalued based on its PB Ratio (14.4x) compared to the AU Medical Equipment industry average (4.5x).


Future Growth

How is Nanosonics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

27.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NAN's forecast earnings growth (27.4% per year) is above the savings rate (1.9%).

Earnings vs Market: NAN's earnings (27.4% per year) are forecast to grow faster than the Australian market (11.4% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: NAN's revenue (15.1% per year) is forecast to grow faster than the Australian market (5.3% per year).

High Growth Revenue: NAN's revenue (15.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NAN's Return on Equity is forecast to be low in 3 years time (13.5%).


Past Performance

How has Nanosonics performed over the past 5 years?

-13.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NAN has high quality earnings.

Growing Profit Margin: NAN's current net profit margins (8.3%) are lower than last year (10.1%).


Past Earnings Growth Analysis

Earnings Trend: NAN's earnings have declined by 13.5% per year over the past 5 years.

Accelerating Growth: NAN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: NAN had negative earnings growth (-15.4%) over the past year, making it difficult to compare to the Medical Equipment industry average (74.9%).


Return on Equity

High ROE: NAN's Return on Equity (6.3%) is considered low.


Financial Health

How is Nanosonics's financial position?


Financial Position Analysis

Short Term Liabilities: NAN's short term assets (A$142.3M) exceed its short term liabilities (A$19.5M).

Long Term Liabilities: NAN's short term assets (A$142.3M) exceed its long term liabilities (A$7.2M).


Debt to Equity History and Analysis

Debt Level: NAN is debt free.

Reducing Debt: NAN had no debt 5 years ago.

Debt Coverage: NAN has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: NAN has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Nanosonics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NAN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NAN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NAN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NAN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NAN's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Michael Kavanagh

7.92yrs

Tenure

AU$1,423,414

Compensation

Mr. Michael C. Kavanagh, BSc, MBA (Advanced,) has been the Chief Executive Officer and President of Nanosonics Limited since October 21, 2013 and served as its Managing Director. Mr. Kavanagh served as a S...


CEO Compensation Analysis

Compensation vs Market: Michael's total compensation ($USD1.03M) is about average for companies of similar size in the Australian market ($USD1.30M).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: NAN's management team is considered experienced (2.7 years average tenure).


Board Members

Experienced Board: NAN's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Nanosonics Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Nanosonics Limited
  • Ticker: NAN
  • Exchange: ASX
  • Founded: 2000
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: AU$1.958b
  • Shares outstanding: 301.62m
  • Website: https://www.nanosonics.com.au

Number of Employees


Location

  • Nanosonics Limited
  • 14 Mars Road
  • Lane Cove
  • New South Wales
  • 2066
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/26 08:05
End of Day Share Price2021/09/24 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.